<DOC>
	<DOCNO>NCT01369862</DOCNO>
	<brief_summary>The purpose phase I/II trial evaluate safety tolerability single dose GHB16L2 administer liquid nasal spray vaccination seasonal influenza virus infection . It also perform assess immunogenicity pharmacokinetics ( shed ) .</brief_summary>
	<brief_title>Study Single Dose GHB16L2 Trivalent Influenza Vaccine Healthy Adults</brief_title>
	<detailed_description>GHB16L2 intend provide novel vaccination influenza virus infection . 80 healthy volunteer include ratio 1:1 GHB16L2 placebo . GHB16L2 administer day 1 . Follow-up visit perform day 2 , 8 29 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female volunteer , 1860 year Seronegative one two applied vaccine strain Low antibody titres H1N1v Written inform consent participate study For female volunteer childbearing potential , provision history current use reliable contraceptive practice Acute febrile illness ( &gt; 37.3°C ) Signs acute chronic upper low tract respiratory illness History severe atopy Seasonal influenza vaccination 2008/2009 and/or late season and/or pandemic influenza vaccination time Fever ≥38.0°C time period prescreening visit day 1 Known increase tendency nose bleed Volunteers clinically relevant abnormal paranasal anatomy Volunteers clinically relevant abnormal laboratory value In female volunteer childbearing potential , positive urine pregnancy test Simultaneous treatment immunosuppressive drug incl . Corticosteroids ( ≥2 week ) within 4 week prior study medication application Clinically relevant history renal , hepatic , GI , cardiovascular , haematological , skin , endocrine , neurological immunological disease History leukaemia cancer HIV Hepatitis B C seropositivity Volunteers underwent rhino sinus surgery , surgery another traumatic injury nose within 30 day prior application study medication Volunteers receive antiviral drug , treatment immunoglobulin blood transfusion , investigational drug within 4 week prior study medication application Volunteers receive antiinflammatory drug 2 day prior study medication application Volunteers likely cope requirement study significant physical mental condition may interfere completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>live attenuate flu vaccine</keyword>
	<keyword>influenza A ( H1N1 )</keyword>
	<keyword>intranasal application</keyword>
	<keyword>replication-deficient influenza virus</keyword>
</DOC>